Evaluating the Adverse Events Associated with Three Doses of the COVID-19 Vaccination in Adults in the Western Region of Saudi Arabia: A Cross-Sectional Study

Overview

Journal Vaccines (Basel)

Date 2023 Feb 28

PMID 36851144

Authors

Hamzah J Aldali

Jehad A Aldali

Badi A Alotaibi

Glowi A Alasiri

Aroob M Alromih

Emadeldin M Elsokkary

Ali Z Aldali

Abdullah Almeziny

Affiliations

Soon will be listed here.

Abstract

The Kingdom of Saudi Arabia was one of the countries earliest affected by the coronavirus 2019 (COVID-19) pandemic and had taken precautions including compulsory COVID-19 vaccination. Both the ChAdOx1 nCoV-19 vaccine (Oxford AstraZeneca) and the BNT162b2 vaccine (Pfizer) were approved by the Saudi Ministry of Health, followed by mRNA-1273 (Moderna), all of which were used for population-wide vaccination. This study aimed to assess the short-term side effects following the COVID-19 vaccinations among participants who had received all three doses in the western region of Saudi Arabia. An online survey was distributed to the participants who received either BNT162b2, ChAdOx1 nCoV-19, or mRNA-1273 vaccines, and the type of side effects and their severity were evaluated. Fatigue and headache, pain at the site of the injection and muscle pain were the most common side effects in all three doses. However, the severity depending on the type of vaccination was significant only for the first and second dose, but not the third dose. In contrast, there was a higher percentage of participants who encountered severe side effects from the third dose compared to the first and second. Nevertheless, the majority of participants described all three doses' side effects to be moderately severe. A future evaluation could be made to access the individual types of vaccination and compare between the side effects of the BNT162b2, ChAdOx1 nCoV-19, and mRNA-1273 vaccines specifically for the booster dose.

Citing Articles

Before and After: Attitude and Adverse Effects Induced by the First and Second Doses of mRNA BNT162b2 Vaccine among Healthcare Professionals in the First Weeks after Their Introduction in Poland.

Pasternak G, Pieniawska-Smiech K, Walkowiak M, Sado J, Pytel A, Jasinska P Vaccines (Basel). 2023; 11(5).

PMID: 37242987 PMC: 10222834. DOI: 10.3390/vaccines11050883.

References

Algaissi A, Alharbi N, Hassanain M, Hashem A . Preparedness and response to COVID-19 in Saudi Arabia: Building on MERS experience. J Infect Public Health. 2020; 13(6):834-838. PMC: 7211706. DOI: 10.1016/j.jiph.2020.04.016. View

Lucas J, Heinlein C, Kim T, Hernandez S, Malik M, True L . The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. Cancer Discov. 2014; 4(11):1310-25. PMC: 4409786. DOI: 10.1158/2159-8290.CD-13-1010. View

Gemmati D, Bramanti B, Serino M, Secchiero P, Zauli G, Tisato V . COVID-19 and Individual Genetic Susceptibility/Receptivity: Role of ACE1/ACE2 Genes, Immunity, Inflammation and Coagulation. Might the Double X-chromosome in Females Be Protective against SARS-CoV-2 Compared to the Single X-Chromosome in Males?. Int J Mol Sci. 2020; 21(10). PMC: 7278991. DOI: 10.3390/ijms21103474. View

Althobaity Y, Wu J, Tildesley M . Non-pharmaceutical interventions and their relevance in the COVID-19 vaccine rollout in Saudi Arabia and Arab Gulf countries. Infect Dis Model. 2022; 7(3):545-560. PMC: 9391232. DOI: 10.1016/j.idm.2022.08.005. View

El-Shitany N, Harakeh S, Badr-Eldin S, Bagher A, Eid B, Almukadi H . Minor to Moderate Side Effects of Pfizer-BioNTech COVID-19 Vaccine Among Saudi Residents: A Retrospective Cross-Sectional Study. Int J Gen Med. 2021; 14:1389-1401. PMC: 8068468. DOI: 10.2147/IJGM.S310497. View

Alshammari T, Altebainawi A, Alenzi K . Importance of early precautionary actions in avoiding the spread of COVID-19: Saudi Arabia as an Example. Saudi Pharm J. 2020; 28(7):898-902. PMC: 7242187. DOI: 10.1016/j.jsps.2020.05.005. View

Alhazmi A, Alamer E, Daws D, Hakami M, Darraj M, Abdelwahab S . Evaluation of Side Effects Associated with COVID-19 Vaccines in Saudi Arabia. Vaccines (Basel). 2021; 9(6). PMC: 8235009. DOI: 10.3390/vaccines9060674. View

Alghamdi A, Alotaibi M, Alqahtani A, Al Aboud D, Abdel-Moneim A . BNT162b2 and ChAdOx1 SARS-CoV-2 Post-vaccination Side-Effects Among Saudi Vaccinees. Front Med (Lausanne). 2021; 8:760047. PMC: 8531069. DOI: 10.3389/fmed.2021.760047. View

Ledford H, Cyranoski D, Van Noorden R . The UK has approved a COVID vaccine - here's what scientists now want to know. Nature. 2020; 588(7837):205-206. DOI: 10.1038/d41586-020-03441-8. View

10.

Choi S, Kim J, Lee J, Kim S, Lee S, Kim S . Hormone Therapy in the Era of the COVID-19 Pandemic: A Review. J Menopausal Med. 2022; 28(1):1-8. PMC: 9086346. DOI: 10.6118/jmm.21036. View

11.

Salam A, Al-Khraif R, Elsegaey I . COVID-19 in Saudi Arabia: An Overview. Front Public Health. 2022; 9:736942. PMC: 8847272. DOI: 10.3389/fpubh.2021.736942. View

12.

Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S . SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020; 181(2):271-280.e8. PMC: 7102627. DOI: 10.1016/j.cell.2020.02.052. View

13.

Wiersinga W, Rhodes A, Cheng A, Peacock S, Prescott H . Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020; 324(8):782-793. DOI: 10.1001/jama.2020.12839. View

14.

Piroth L, Cottenet J, Mariet A, Bonniaud P, Blot M, Tubert-Bitter P . Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study. Lancet Respir Med. 2020; 9(3):251-259. PMC: 7832247. DOI: 10.1016/S2213-2600(20)30527-0. View

15.

Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020; 397(10269):99-111. PMC: 7723445. DOI: 10.1016/S0140-6736(20)32661-1. View

16.

Salvagno G, Henry B, di Piazza G, Pighi L, De Nitto S, Bragantini D . Anti-SARS-CoV-2 Receptor-Binding Domain Total Antibodies Response in Seropositive and Seronegative Healthcare Workers Undergoing COVID-19 mRNA BNT162b2 Vaccination. Diagnostics (Basel). 2021; 11(5). PMC: 8147939. DOI: 10.3390/diagnostics11050832. View

17.

Menni C, May A, Polidori L, Louca P, Wolf J, Capdevila J . COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study. Lancet Infect Dis. 2022; 22(7):1002-1010. PMC: 8993156. DOI: 10.1016/S1473-3099(22)00146-3. View

18.

Abu Jabal K, Ben-Amram H, Beiruti K, Batheesh Y, Sussan C, Zarka S . Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021. Euro Surveill. 2021; 26(6). PMC: 7879501. DOI: 10.2807/1560-7917.ES.2021.26.6.2100096. View

19.

Shrotri M, Swinnen T, Kampmann B, Parker E . An interactive website tracking COVID-19 vaccine development. Lancet Glob Health. 2021; 9(5):e590-e592. PMC: 8049589. DOI: 10.1016/S2214-109X(21)00043-7. View

20.

Farhat M, Al-Ibrahim R, Almohammedali A, Aljishi R, Alalwan B . Study of the Side Effects of Pfizer and Oxford COVID-19 Vaccines in the Eastern Province of Saudi Arabia. Int J Gen Med. 2022; 15:7547-7558. PMC: 9527030. DOI: 10.2147/IJGM.S379204. View